PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CRBP vs. PRME
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CRBP and PRME is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

CRBP vs. PRME - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Prime Medicine Inc. Common Stock (PRME). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-87.33%
-25.36%
CRBP
PRME

Key characteristics

Sharpe Ratio

CRBP:

-0.62

PRME:

-0.69

Sortino Ratio

CRBP:

-0.42

PRME:

-0.87

Omega Ratio

CRBP:

0.94

PRME:

0.91

Calmar Ratio

CRBP:

-0.67

PRME:

-0.65

Martin Ratio

CRBP:

-1.32

PRME:

-1.12

Ulcer Index

CRBP:

49.35%

PRME:

51.59%

Daily Std Dev

CRBP:

106.22%

PRME:

84.11%

Max Drawdown

CRBP:

-99.31%

PRME:

-89.20%

Current Drawdown

CRBP:

-97.49%

PRME:

-84.45%

Fundamentals

Market Cap

CRBP:

$95.00M

PRME:

$430.86M

EPS

CRBP:

-$4.71

PRME:

-$2.06

Total Revenue (TTM)

CRBP:

$0.00

PRME:

$38.57M

Gross Profit (TTM)

CRBP:

-$351.69K

PRME:

$37.26M

EBITDA (TTM)

CRBP:

-$31.87M

PRME:

-$153.83M

Returns By Period

In the year-to-date period, CRBP achieves a -33.90% return, which is significantly lower than PRME's 12.50% return.


CRBP

YTD

-33.90%

1M

-34.56%

6M

-87.33%

1Y

-66.52%

5Y*

-45.80%

10Y*

-19.08%

PRME

YTD

12.50%

1M

13.67%

6M

-25.34%

1Y

-59.09%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CRBP vs. PRME — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRBP
The Risk-Adjusted Performance Rank of CRBP is 1515
Overall Rank
The Sharpe Ratio Rank of CRBP is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of CRBP is 2121
Sortino Ratio Rank
The Omega Ratio Rank of CRBP is 2020
Omega Ratio Rank
The Calmar Ratio Rank of CRBP is 99
Calmar Ratio Rank
The Martin Ratio Rank of CRBP is 1010
Martin Ratio Rank

PRME
The Risk-Adjusted Performance Rank of PRME is 1414
Overall Rank
The Sharpe Ratio Rank of PRME is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of PRME is 1313
Sortino Ratio Rank
The Omega Ratio Rank of PRME is 1616
Omega Ratio Rank
The Calmar Ratio Rank of PRME is 1010
Calmar Ratio Rank
The Martin Ratio Rank of PRME is 1818
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CRBP vs. PRME - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Prime Medicine Inc. Common Stock (PRME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CRBP, currently valued at -0.62, compared to the broader market-2.000.002.00-0.62-0.69
The chart of Sortino ratio for CRBP, currently valued at -0.42, compared to the broader market-4.00-2.000.002.004.006.00-0.42-0.87
The chart of Omega ratio for CRBP, currently valued at 0.94, compared to the broader market0.501.001.502.000.940.91
The chart of Calmar ratio for CRBP, currently valued at -0.75, compared to the broader market0.002.004.006.00-0.75-0.65
The chart of Martin ratio for CRBP, currently valued at -1.32, compared to the broader market0.0010.0020.0030.00-1.32-1.12
CRBP
PRME

The current CRBP Sharpe Ratio is -0.62, which is comparable to the PRME Sharpe Ratio of -0.69. The chart below compares the historical Sharpe Ratios of CRBP and PRME, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.62
-0.69
CRBP
PRME

Dividends

CRBP vs. PRME - Dividend Comparison

Neither CRBP nor PRME has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CRBP vs. PRME - Drawdown Comparison

The maximum CRBP drawdown since its inception was -99.31%, which is greater than PRME's maximum drawdown of -89.20%. Use the drawdown chart below to compare losses from any high point for CRBP and PRME. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-87.33%
-84.45%
CRBP
PRME

Volatility

CRBP vs. PRME - Volatility Comparison

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a higher volatility of 28.11% compared to Prime Medicine Inc. Common Stock (PRME) at 25.56%. This indicates that CRBP's price experiences larger fluctuations and is considered to be riskier than PRME based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
28.11%
25.56%
CRBP
PRME

Financials

CRBP vs. PRME - Financials Comparison

This section allows you to compare key financial metrics between Corbus Pharmaceuticals Holdings, Inc. and Prime Medicine Inc. Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab